In breast cancer, Cui and colleagues demonstrated that ectopic FOXC1 expression in ERα-positive MCF7 luminal breast cancer cells greatly diminished the effects of growth-stimulatory B-estradiol and growth-inhibitory antiestrogen treatment with Tamoxifen and Fulvestrant (76). This evidence concerns the gene FOXC1 and breast carcinoma.